Oncology Peer Review On-The-Go: 1-on-1 with Dr. Michael Randell: New ACS Guidelines for Cervical Cancer

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.

In this interview we discuss a recent study that found that more than half of patients with locally advanced cervical cancer in the United States did not receive standard of care.

Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.

Data from the phase 3 CALLA trial indicated that multidisciplinary collaboration and a good quality control strategy are key to providing optimal chemoradiotherapy delivery in locally advanced cervical cancer.